Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a strong sell rating to a hold rating in a report published on Tuesday, Zacks.com reports. They currently have $35.00 target price on the stock.

According to Zacks, “A wide range of dialysis products and services instill optimism in Fresenius Medical. The company’s new program to provide support to its 2025 strategy, which is aimed at boosting profitability and compensating for the negative earnings impact of the pandemic, has been in line with its expectations. The company benefited from revenue growth across Asia Pacific and Latin America regions. Strength in Health Care Services in the quarter under review is encouraging. Yet, Fresenius Medical exited the third quarter on a mixed note. The company witnessed revenue decline in the EMEA region. Weakness across Health Care Products units is a woe. Fresenius Medical faces intense competition in the field of health care services and sale of dialysis products, which remains a headwind. Over the past year, the stock has underperformed the industry.”

Several other equities research analysts also recently issued reports on FMS. HSBC assumed coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, November 23rd. They set a hold rating on the stock. Berenberg Bank reissued a buy rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, November 10th. Truist dropped their target price on shares of Fresenius Medical Care AG & Co. KGaA from $44.00 to $40.00 and set a hold rating for the company in a research report on Wednesday, October 13th. Barclays reissued an equal weight rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Thursday, October 21st. Finally, Truist Securities dropped their target price on shares of Fresenius Medical Care AG & Co. KGaA from $44.00 to $40.00 and set a hold rating for the company in a research report on Wednesday, October 13th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of Hold and a consensus target price of $37.50.

Fresenius Medical Care AG & Co. KGaA stock opened at $33.80 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $29.71 and a 12-month high of $42.46. The company has a market capitalization of $19.81 billion, a price-to-earnings ratio of 18.07 and a beta of 1.26. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.78. The firm’s fifty day moving average price is $31.78 and its 200 day moving average price is $35.83.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Tuesday, November 2nd. The company reported $0.55 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.55. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.28% and a return on equity of 8.74%. The firm had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.37 billion. Analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.96 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. Liberty Wealth Management LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 71.9% during the 3rd quarter. Liberty Wealth Management LLC now owns 1,234 shares of the company’s stock valued at $42,000 after purchasing an additional 516 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in Fresenius Medical Care AG & Co. KGaA by 113.1% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,321 shares of the company’s stock valued at $55,000 after purchasing an additional 701 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its stake in Fresenius Medical Care AG & Co. KGaA by 98.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 1,733 shares of the company’s stock valued at $61,000 after purchasing an additional 859 shares during the period. FORA Capital LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 2nd quarter valued at about $76,000. Finally, Annapolis Financial Services LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 3rd quarter valued at about $81,000. 4.42% of the stock is owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Read More: How interest rates affect municipal bond prices

Get a free copy of the Zacks research report on Fresenius Medical Care AG & Co. KGaA (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.